ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
USE OF THE CNS AGENT BREMELANOTIDE IN MEN WITH SEXUAL DYSFUNCTION: RESULTS FROM A SEXUAL MEDICINE CLINIC
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 279449" data-attributes="member: 13851"><p><strong>INTRODUCTION AND OBJECTIVE</strong></p><p></p><p><em>Bremelanotide is FDA approved for premenopausal women with generalized, acquired hypoactive sexual desire disorder (HSDD). <strong>It modulates dopaminergic pathways involved in sexual desire and arousal in men and women and has been reported to increase genital blood flow within hours of subcutaneous administration. We have been prescribing bremelanotide off-label to men with sexual dysfunctions (SD) after undergoing a biopsychosocial evaluation.</strong> <strong>The aim was to better understand the use at our clinic of bremelanotide in men, evaluating improvements in sexual function, overall satisfaction, and side effects.</strong></em></p><p></p><p></p><p><strong>METHODS</strong></p><p></p><p><em>Bremelanotide prescription dispensing data from our facility was compiled from September 2019 to June 30, 2023 and analyzed for prescribing patterns and refill rates.<strong> We performed a one-group study design for men with SD who were prescribed bremelanotide. Participants answered the Quality of Life Dimension of Sexual Quality of Life Questionnaire, Patient Global Impression of Improvement (PGI-I) and General Assessment Questions online. Participants completed a structured interview over the telephone with a single interviewer. Descriptive statistics characterized the study cohort. Adverse events were collected.</strong></em></p><p></p><p></p><p><strong>RESULTS</strong></p><p></p><p><em>Over the 46-months, bremelanotide has been dispensed to men for SD 444 times; 65% of dispenses were refills. Over a recent 18 period, refill rates have been 73% (n=219). <strong>25 men signed consent and 20 completed the online questionnaires. 75% of these men were more satisfied with their lovemaking and duration of lovemaking; 88% reported vaginal insertion was easier and 67% said it was easier to orgasm. Concerning feelings about initiating lovemaking, 80% were more at ease and 73% anticipated it would be more pleasurable and more carefree. 64% believed orgasm was more pleasurable and 69% said that lovemaking was more pleasurable while 73% reported that the partner’s overall experience was more pleasurable. Using the PGI-I, 72% of participants felt that sexual function after using bremelanotide was a little better, much better, or very much better. Side effects included nausea (30%), flushing (22%), headache (13%), bothersome spontaneous erections without sexual stimulation for about 24 hours after injection (13%), and incontinence, cramping and abdominal burning (4% each). All adverse events were transient.</strong></em></p><p></p><p></p><p><strong>CONCLUSIONS</strong></p><p></p><p><em><strong>Bremelanotide acts <u>centrally by raising dopamine</u>, unlike PDE5 inhibitors that act peripherally. Our study showed that <u>bremelanotide safely and effectively improved SD for some men</u>.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 279449, member: 13851"] [B]INTRODUCTION AND OBJECTIVE[/B] [I]Bremelanotide is FDA approved for premenopausal women with generalized, acquired hypoactive sexual desire disorder (HSDD). [B]It modulates dopaminergic pathways involved in sexual desire and arousal in men and women and has been reported to increase genital blood flow within hours of subcutaneous administration. We have been prescribing bremelanotide off-label to men with sexual dysfunctions (SD) after undergoing a biopsychosocial evaluation.[/B] [B]The aim was to better understand the use at our clinic of bremelanotide in men, evaluating improvements in sexual function, overall satisfaction, and side effects.[/B][/I] [B]METHODS[/B] [I]Bremelanotide prescription dispensing data from our facility was compiled from September 2019 to June 30, 2023 and analyzed for prescribing patterns and refill rates.[B] We performed a one-group study design for men with SD who were prescribed bremelanotide. Participants answered the Quality of Life Dimension of Sexual Quality of Life Questionnaire, Patient Global Impression of Improvement (PGI-I) and General Assessment Questions online. Participants completed a structured interview over the telephone with a single interviewer. Descriptive statistics characterized the study cohort. Adverse events were collected.[/B][/I] [B]RESULTS[/B] [I]Over the 46-months, bremelanotide has been dispensed to men for SD 444 times; 65% of dispenses were refills. Over a recent 18 period, refill rates have been 73% (n=219). [B]25 men signed consent and 20 completed the online questionnaires. 75% of these men were more satisfied with their lovemaking and duration of lovemaking; 88% reported vaginal insertion was easier and 67% said it was easier to orgasm. Concerning feelings about initiating lovemaking, 80% were more at ease and 73% anticipated it would be more pleasurable and more carefree. 64% believed orgasm was more pleasurable and 69% said that lovemaking was more pleasurable while 73% reported that the partner’s overall experience was more pleasurable. Using the PGI-I, 72% of participants felt that sexual function after using bremelanotide was a little better, much better, or very much better. Side effects included nausea (30%), flushing (22%), headache (13%), bothersome spontaneous erections without sexual stimulation for about 24 hours after injection (13%), and incontinence, cramping and abdominal burning (4% each). All adverse events were transient.[/B][/I] [B]CONCLUSIONS[/B] [I][B]Bremelanotide acts [U]centrally by raising dopamine[/U], unlike PDE5 inhibitors that act peripherally. Our study showed that [U]bremelanotide safely and effectively improved SD for some men[/U].[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
USE OF THE CNS AGENT BREMELANOTIDE IN MEN WITH SEXUAL DYSFUNCTION: RESULTS FROM A SEXUAL MEDICINE CLINIC
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top